Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease.
Objective: To estimate the proportion of individuals with established Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Disease (CVD) who are receiving pharmacological anti-diabetic treatment with evidence of cardiovascular benefit at a hospital in Argentina. Materials and Methods: Cross-sectional...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artículo revista |
| Lenguaje: | Español |
| Publicado: |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología
2023
|
| Materias: | |
| Acceso en línea: | https://revistas.unc.edu.ar/index.php/med/article/view/42272 |
| Aporte de: |
| id |
I10-R327-article-42272 |
|---|---|
| record_format |
ojs |
| institution |
Universidad Nacional de Córdoba |
| institution_str |
I-10 |
| repository_str |
R-327 |
| container_title_str |
Revista de la Facultad de Ciencias Médicas de Córdoba |
| language |
Español |
| format |
Artículo revista |
| topic |
diabetes mellitus type 2 cardiovascular diseases hypoglycemic agents sodium-glucose cotransporter 2 inhibitors liraglutide diabetes mellitus tipo 2 enfermedades cardiovasculares hipoglucemiantes inhibidores del cotransportador de odio-Glucosa 2 inhibidores del cotransportador de sodio-glucosa 2 liraglutida diabetes mellitus Tipo 2 doenças cardiovasculares agentes Hipoglicemiantes Inibidores do Cotransportador Sódio-Glicose 2 liraglutida |
| spellingShingle |
diabetes mellitus type 2 cardiovascular diseases hypoglycemic agents sodium-glucose cotransporter 2 inhibitors liraglutide diabetes mellitus tipo 2 enfermedades cardiovasculares hipoglucemiantes inhibidores del cotransportador de odio-Glucosa 2 inhibidores del cotransportador de sodio-glucosa 2 liraglutida diabetes mellitus Tipo 2 doenças cardiovasculares agentes Hipoglicemiantes Inibidores do Cotransportador Sódio-Glicose 2 liraglutida Pintos, Carolina Burgos, Mariana Andrea Pasik, Natalia Inés Piccioli, Sofía Grande Ratti, María Florencia Russo, María Paula Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. |
| topic_facet |
diabetes mellitus type 2 cardiovascular diseases hypoglycemic agents sodium-glucose cotransporter 2 inhibitors liraglutide diabetes mellitus tipo 2 enfermedades cardiovasculares hipoglucemiantes inhibidores del cotransportador de odio-Glucosa 2 inhibidores del cotransportador de sodio-glucosa 2 liraglutida diabetes mellitus Tipo 2 doenças cardiovasculares agentes Hipoglicemiantes Inibidores do Cotransportador Sódio-Glicose 2 liraglutida |
| author |
Pintos, Carolina Burgos, Mariana Andrea Pasik, Natalia Inés Piccioli, Sofía Grande Ratti, María Florencia Russo, María Paula |
| author_facet |
Pintos, Carolina Burgos, Mariana Andrea Pasik, Natalia Inés Piccioli, Sofía Grande Ratti, María Florencia Russo, María Paula |
| author_sort |
Pintos, Carolina |
| title |
Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. |
| title_short |
Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. |
| title_full |
Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. |
| title_fullStr |
Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. |
| title_full_unstemmed |
Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. |
| title_sort |
real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. |
| description |
Objective: To estimate the proportion of individuals with established Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Disease (CVD) who are receiving pharmacological anti-diabetic treatment with evidence of cardiovascular benefit at a hospital in Argentina.
Materials and Methods: Cross-sectional study conducted at the Italian Hospital of Buenos Aires. A consecutive sample of adult patients affiliated with the institutional prepaid health plan active in March 2020, diagnosed with T2DM and established CVD, was included. Data were collected from the Electronic Health Record. The proportion of pharmacological adequacy (combined use of metformin plus sodium-glucose co-transporter 2 inhibitors and/or glucagon-like peptide 1 receptor agonists) was reported along with its respective 95% confidence interval (CI).
Results: A total of 1539 patients were included, with a mean age of 76.2 years; 65.3% were male, and 81.6% were overweight or obese. Hemoglobin A1c levels were recorded in the past year for 74.9% of patients, with an average value of 6.9% (SD 1.2). The most prescribed drugs were metformin (61.3%), insulin (26.7%), and gliptins (11%). Out of the total included patients, 82 exhibited pharmacotherapeutic adequacy for diabetes treatment, with a prevalence of 5.3% (95% CI 4.2-6.5).
Conclusions: The prevalence of prescribing anti-diabetic drugs with evidence of cardiovascular benefit was 5.3% (95% CI 4.2-6.5). This real-world evidence highlights the low frequency of prescribing this type of medication at the time of the study in a high cardiovascular risk population. |
| publisher |
Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología |
| publishDate |
2023 |
| url |
https://revistas.unc.edu.ar/index.php/med/article/view/42272 |
| work_keys_str_mv |
AT pintoscarolina realworldevidenceonpharmacologicalappropriatenessintype2diabetesmellitusandcardiovasculardisease AT burgosmarianaandrea realworldevidenceonpharmacologicalappropriatenessintype2diabetesmellitusandcardiovasculardisease AT pasiknataliaines realworldevidenceonpharmacologicalappropriatenessintype2diabetesmellitusandcardiovasculardisease AT picciolisofia realworldevidenceonpharmacologicalappropriatenessintype2diabetesmellitusandcardiovasculardisease AT granderattimariaflorencia realworldevidenceonpharmacologicalappropriatenessintype2diabetesmellitusandcardiovasculardisease AT russomariapaula realworldevidenceonpharmacologicalappropriatenessintype2diabetesmellitusandcardiovasculardisease AT pintoscarolina evidenciademundorealsobreadecuacionfarmacologicaendiabetestipo2yenfermedadcardiovascular AT burgosmarianaandrea evidenciademundorealsobreadecuacionfarmacologicaendiabetestipo2yenfermedadcardiovascular AT pasiknataliaines evidenciademundorealsobreadecuacionfarmacologicaendiabetestipo2yenfermedadcardiovascular AT picciolisofia evidenciademundorealsobreadecuacionfarmacologicaendiabetestipo2yenfermedadcardiovascular AT granderattimariaflorencia evidenciademundorealsobreadecuacionfarmacologicaendiabetestipo2yenfermedadcardiovascular AT russomariapaula evidenciademundorealsobreadecuacionfarmacologicaendiabetestipo2yenfermedadcardiovascular AT pintoscarolina evidenciadomundorealsobreadequacaofarmacologicanadiabetesmellitustipo2edoencacardiovascular AT burgosmarianaandrea evidenciadomundorealsobreadequacaofarmacologicanadiabetesmellitustipo2edoencacardiovascular AT pasiknataliaines evidenciadomundorealsobreadequacaofarmacologicanadiabetesmellitustipo2edoencacardiovascular AT picciolisofia evidenciadomundorealsobreadequacaofarmacologicanadiabetesmellitustipo2edoencacardiovascular AT granderattimariaflorencia evidenciadomundorealsobreadequacaofarmacologicanadiabetesmellitustipo2edoencacardiovascular AT russomariapaula evidenciadomundorealsobreadequacaofarmacologicanadiabetesmellitustipo2edoencacardiovascular |
| first_indexed |
2024-09-03T21:04:35Z |
| last_indexed |
2024-09-03T21:04:35Z |
| _version_ |
1809210383392571392 |
| spelling |
I10-R327-article-422722024-04-24T19:04:13Z Real-world evidence on pharmacological appropriateness in type 2 diabetes mellitus and cardiovascular disease. Evidencia de mundo real sobre adecuación farmacológica en diabetes tipo 2 y enfermedad cardiovascular Evidência do mundo real sobre adequação farmacológica na diabetes mellitus tipo 2 e doença cardiovascular. Pintos, Carolina Burgos, Mariana Andrea Pasik, Natalia Inés Piccioli, Sofía Grande Ratti, María Florencia Russo, María Paula diabetes mellitus type 2 cardiovascular diseases hypoglycemic agents sodium-glucose cotransporter 2 inhibitors liraglutide diabetes mellitus tipo 2 enfermedades cardiovasculares hipoglucemiantes inhibidores del cotransportador de odio-Glucosa 2 inhibidores del cotransportador de sodio-glucosa 2 liraglutida diabetes mellitus Tipo 2 doenças cardiovasculares agentes Hipoglicemiantes Inibidores do Cotransportador Sódio-Glicose 2 liraglutida Objective: To estimate the proportion of individuals with established Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Disease (CVD) who are receiving pharmacological anti-diabetic treatment with evidence of cardiovascular benefit at a hospital in Argentina. Materials and Methods: Cross-sectional study conducted at the Italian Hospital of Buenos Aires. A consecutive sample of adult patients affiliated with the institutional prepaid health plan active in March 2020, diagnosed with T2DM and established CVD, was included. Data were collected from the Electronic Health Record. The proportion of pharmacological adequacy (combined use of metformin plus sodium-glucose co-transporter 2 inhibitors and/or glucagon-like peptide 1 receptor agonists) was reported along with its respective 95% confidence interval (CI). Results: A total of 1539 patients were included, with a mean age of 76.2 years; 65.3% were male, and 81.6% were overweight or obese. Hemoglobin A1c levels were recorded in the past year for 74.9% of patients, with an average value of 6.9% (SD 1.2). The most prescribed drugs were metformin (61.3%), insulin (26.7%), and gliptins (11%). Out of the total included patients, 82 exhibited pharmacotherapeutic adequacy for diabetes treatment, with a prevalence of 5.3% (95% CI 4.2-6.5). Conclusions: The prevalence of prescribing anti-diabetic drugs with evidence of cardiovascular benefit was 5.3% (95% CI 4.2-6.5). This real-world evidence highlights the low frequency of prescribing this type of medication at the time of the study in a high cardiovascular risk population. Objetivo: Estimar la proporción de personas con Diabetes Mellitus tipo 2 (DM2) y Enfermedad Cardiovascular (ECV) establecida que reciben tratamiento farmacológico anti-diabético con evidencia de beneficio cardiovascular en un hospital en Argentina. Materiales y Métodos: Estudio de corte transversal realizado en el Hospital Italiano de Buenos Aires. Se incluyó una muestra consecutiva de pacientes adultos afiliados a prepaga institucional activos a Marzo 2020, con diagnóstico de DM2 y ECV establecida. Los datos se tomaron de la Historia Clínica Electrónica. Se informó la proporción de adecuación farmacológica (uso combinado de metformina más inhibidores del cotransportador de sodio glucosa tipo 2 y/o agonistas del Péptido Similar al Glucagón tipo 1) con su respectivo IC95%. Resultados. Se incluyeron 1539 pacientes, con una media de edad 76,2 años, 65,3% eran de sexo masculino, 81,6% con sobrepeso u obesidad. Un 74,9% de los pacientes tenían registro de hemoglobina glicosilada en el último año, con un valor promedio de 6,9% (DE 1,2). Las drogas más prescritas fueron: metformina (61,3%), insulina (26,7%), y gliptinas (11%). Del total de pacientes incluidos, 82 presentaron adecuación fármaco-terapéutica antidiabética, con una prevalencia de 5,3% (IC95% 4,2-6,5). Conclusiones. La prevalencia de prescripción de drogas antidiabéticas con evidencia de beneficio cardiovascular fue de 5,3% (IC95% 4,2-6,5). Esta información extraída de evidencia del mundo real identifica la baja frecuencia de prescripción de este tipo de fármacos al momento del estudio en una población de alto riesgo cardiovascular. Objetivo: Estimar a proporção de indivíduos com Diabetes Mellitus tipo 2 (DM2) estabelecida e Doença Cardiovascular (DCV) que estão recebendo tratamento farmacológico anti-diabético com evidência de benefício cardiovascular em um hospital na Argentina. Materiais e Métodos: Estudo transversal realizado no Hospital Italiano de Buenos Aires. Uma amostra consecutiva de pacientes adultos afiliados ao plano de saúde pré-pago institucional ativo em março de 2020, diagnosticados com DM2 e DCV estabelecida, foi incluída. Os dados foram coletados do Registro Eletrônico de Saúde. A proporção de adequação farmacológica (uso combinado de metformina mais inibidores do co-transportador de sódio-glicose tipo 2 e/ou agonistas do receptor do peptídeo semelhante ao glucagon tipo 1) foi relatada juntamente com seu respectivo intervalo de confiança de 95% (IC). Resultados: Um total de 1539 pacientes foram incluídos, com idade média de 76,2 anos; 65,3% eram do sexo masculino e 81,6% estavam com sobrepeso ou obesidade. Os níveis de hemoglobina A1c foram registrados no último ano para 74,9% dos pacientes, com valor médio de 6,9% (DP 1,2). Os medicamentos mais prescritos foram metformina (61,3%), insulina (26,7%) e gliptinas (11%). Do total de pacientes incluídos, 82 apresentaram adequação farmacoterapêutica para o tratamento do diabetes, com uma prevalência de 5,3% (IC 95% 4,2-6,5). Conclusões: A prevalência de prescrição de medicamentos anti-diabéticos com evidência de benefício cardiovascular foi de 5,3% (IC 95% 4,2-6,5). Essa evidência do mundo real destaca a baixa frequência de prescrição desse tipo de medicação no momento do estudo em uma população de alto risco cardiovascular. Universidad Nacional Córdoba. Facultad de Ciencias Médicas. Secretaria de Ciencia y Tecnología 2023-12-26 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion text/html application/pdf https://revistas.unc.edu.ar/index.php/med/article/view/42272 10.31053/1853.0605.v80.n4.42272 Revista de la Facultad de Ciencias Médicas de Córdoba.; Vol. 80 No. 4 (2023): Publicaciones especiales por 80° Aniversario; 335-351 Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 80 Núm. 4 (2023): Publicaciones especiales por 80° Aniversario; 335-351 Revista da Faculdade de Ciências Médicas de Córdoba; v. 80 n. 4 (2023): Publicaciones especiales por 80° Aniversario; 335-351 1853-0605 0014-6722 10.31053/1853.0605.v80.n4 spa https://revistas.unc.edu.ar/index.php/med/article/view/42272/44332 https://revistas.unc.edu.ar/index.php/med/article/view/42272/44118 Derechos de autor 2023 Universidad Nacional de Córdoba http://creativecommons.org/licenses/by-nc/4.0 |